Spenser Lin No Comments

Healthcare News, Deals, and Investments Update August 31st, 2026

LECO_Weekly-Healthcare-News_8-31-2026Download

Healthcare Weekly News and Deals

  1. Sword Health to acquire OrangeDot, the parent company of Headspace, in an all-cash transaction reported between $200-$300 million. Sword Health, last valued at about $4 billion after raising just under $500 million, is buying OrangeDot for cash, with OrangeDot surviving as a wholly owned subsidiary. The $200–300 million range is a severe markdown against the roughly $3 billion at which Headspace and Ginger combined in 2021 and sits below the $321 million Headspace had raised. The deal follows Sword’s $285 million purchase of Kaia Health and extends its move from musculoskeletal care into behavioural health alongside its Mind and Dawn products. The Massachusetts filing dates from 22 July; the effective date is 14 September. (Link)
  2. American Healthcare REIT, Inc. (NYSE: AHR) has completed a $197 million acquisition of two Northern California senior housing communities from a joint venture between Affinius Capital and Alliance Residential Co. American Healthcare REIT has bought Sonrisa Senior Living in Roseville, rebranded Avella at Roseville, and The Watermark at Almaden, 545 units in total, for $197 million. Sonrisa alone traded at $94.1 million. The buyer has now completed roughly $1.4 billion of senior living acquisitions in 2026 and is pursuing a pipeline including $953 million under executed agreements, among them an $873 million Kensington portfolio. Senior housing occupancy reached 89.9% in the second quarter. Note the source headline wrongly casts the REIT as seller. (Link)
  3. Thomas Park Investments has acquired a four-property, $70 million medical outpatient portfolio from Stewart Investment Properties. The Annapolis healthcare real estate platform paid $70 million for 165,637 square feet across three Mid-Atlantic submarkets. The package is 1420 Beverly Road in McLean, a 47,185-square-foot building fully leased and anchored by MedStar Health; 6849 Old Dominion Drive in McLean, 69,330 square feet and 89% leased with Johns Hopkins Medicine as anchor; Children’s National at the former Takoma Theatre on Fourth Street NW in Washington, 24,140 square feet; and Luminis Health Easton Pavilion in Easton, Maryland, 24,982 square feet and fully leased to Luminis Health. Each asset is health-system anchored with remaining term and contractual rent growth. (Link)
  4. Ambulatory Partner Holdings has agreed to pay $54 million for a 60% stake in Atlas Surgery Center, the physician-owned neurosurgical ASC in Amherst, New York. Ambulatory Partner Holdings, an LLC owned equally by Rafael Axen, M.D., Matthew Jenkins and Ann Sariego, is buying 60% from seven of the nine physician members who together hold 90%.. Atlas, at 50 George Karl Boulevard, is a multispecialty Article 28 centre known for outpatient neurosurgery, angiograms, carotid stenting and complex spine, running on the order of 3,000 cases a year. Purchase price is equity-funded. New York’s Public Health and Health Planning Council has the establishment application on its 17 September agenda. (Link)
  5. The Federal Trade Commission has approved the final consent order clearing Ascension Health Alliance’s $3.9 billion acquisition of AmSurg LLC. The FTC finalised its order on 25 August, letting Ascension close a $3.9 billion purchase first agreed in mid-2025. Six centres go to SC Affiliates, a national ASC operator, and a seventh in Panama City to Florida Gastroenterology Center, a physician group already holding a minority stake. The divestitures cover Nashville, Panama City, Tulsa, Waco and Wichita, where the agency alleged reduced competition in gastroenterology, ophthalmology and orthopaedic outpatient procedures. Ascension must also give the FTC prior notice of ASC acquisitions in those metros for ten years. AmSurg operates more than 250 centres across 34 states. (Link)
  6. McKesson Corporation (NYSE: MCK) has signed a definitive agreement to acquire Precision Medicine Group, LLC from Blackstone (NYSE: BX) for approximately $2.25 billion. McKesson is paying roughly $2.25 billion for the Bethesda-based business after a multi-year Blackstone hold. The buyer is underwriting a services asset rather than a distribution one: biomarker intelligence, laboratory services, a global CRO, market access consulting and commercialisation support. That fits a portfolio McKesson has been reshaping by shedding non-core assets and concentrating capital in oncology and specialty, where Oncology & Multispecialty revenue rose 33% to $14.2 billion in fiscal first quarter 2026. The target will report inside that segment. Closing is subject to customary conditions and regulatory clearances. (Link)
  7. Eli Lilly and Company (NYSE: LLY) to acquire Merida Biosciences for up to $2.875 billion in cash, adding a precision immunology platform aimed at pathogenic autoantibodies. Consideration is cash up to $2.875 billion, covering an undisclosed upfront payment and contingent milestones. Cambridge-based Merida is building biologics that selectively degrade disease-causing antibodies while sparing normal immune function. Lead program MER511 is in Phase 1 for Graves’ disease and thyroid eye disease, with initial data showing reductions in pathogenic thyroid-stimulating antibodies and a favourable safety profile. A preclinical program, MER769, targets food allergy, asthma and chronic spontaneous urticaria. Merida launched last year with a $121 million Series A co-led by Bain Capital Life Sciences, BVF Partners and Third Rock Ventures. Close is expected in the fourth quarter, subject to customary clearances. (Link)
  8. Argenx SE (Euronext & Nasdaq: ARGX) completed a $2.2 billion all-cash acquisition of Forte Biosciences, Inc. (Nasdaq: FBRX) at $77.00 per share. The close, announced 27 August, follows a cash tender that drew about 87% of Forte shares. The deal adds FB102, which has clinical proof-of-concept in vitiligo and celiac disease and potential application across multiple autoimmune indications, to argenx’s immunology portfolio. The original agreement was signed 27 July at a 40.5% premium to Forte’s then-close. The transaction extends a 2026 pattern of large-cap immunology buyers paying for de-risked, mechanism-differentiated assets rather than waiting for later-stage readouts. Forte is now a wholly owned subsidiary and will delist from Nasdaq. (Link)
  9. Advent International has signed a definitive agreement to acquire a majority stake in New Zealand Clinical Research Group in a transaction local press valued at roughly NZ$1 billion, with Waterman Capital and clinician shareholders rolling over. Advent, one of the largest global private equity firms, is buying majority control of NZCR Group, a physician-led clinical trials platform operating across New Zealand and Australia under the NZCR, CMAX, Optimal and Fusion brands. Advent’s own release did not print a price; BusinessDesk and the Australian Financial Review put the equity value at about NZ$1 billion. Waterman Capital, which held 52%, and clinician shareholders are keeping a significant minority. Close is targeted for the fourth quarter subject to regulatory approvals. Advent will partner with CEO Tony Moffatt to deepen sponsor relationships and extend the network internationally. (Link)
  10. Radiology Partners has signed a definitive agreement to acquire Everlight Radiology from UK private equity firm Livingbridge in a cross-border teleradiology transaction reported at roughly $1 billion (approximately A$1 billion, or about US$715 million). Livingbridge is exiting Everlight after taking majority control in 2021 for a reported US$344 million, having itself bought the asset from Intermediate Capital Group. Everlight’s 800-plus consultant radiologists across 40-plus countries read on a follow-the-sun basis, roughly 2.5 million exams a year for 340-plus clients, avoiding premium US night-shift rates. Radiology Partners intends to extend Mosaic Drafting AI across the acquired network. The 17 August edition covered Livingbridge putting the asset up for sale with Radiology Partners named as bidder; this is the signed agreement. Regulatory clearances pending. (Link)
  11. TowerBrook Capital Partners to acquire a majority stake in Korean-American women’s wellness brand Rael for 400 billion won ($290 million), buying out a shareholder register including SoftBank Ventures, Unilever Ventures, Lotte Shopping, Shinsegae and GS Retail. TowerBrook is paying 400 billion won, about $290 million, for majority control of Rael, according to people familiar with the matter. The sponsor is buying a consumer health asset with a proven digital channel: Rael became Amazon’s top-selling sanitary pad label on an organic feminine care proposition. The cap table it is taking out is unusually broad for a brand of this size, spanning venture investors SoftBank Ventures and Unilever Ventures alongside strategic Korean retail capital from Lotte Shopping, Shinsegae and GS Retail. The deal is a rare cross-border consumer exit for Korean sponsors in a market skewed toward beauty. (Link)
  12. BioXcel Therapeutics, Inc. (Nasdaq: BTAI) has filed Chapter 11 and entered a stalking-horse sale with Teva Pharmaceuticals at $57.5 million upfront with milestones up to $125 million. BioXcel and two OnkosXcel subsidiaries petitioned in Delaware on 27 August to run a court-supervised 363 sale of substantially all assets. Teva Pharmaceuticals International GmbH is the stalking-horse bidder for $57.5 million in cash, assumption of specified liabilities, and up to $67.5 million of contingent development payments — a ceiling of $125 million if milestones hit. The estate includes IGALMI, the approved dexmedetomidine sublingual film for agitation, and the pending BXCL501 at-home filing. Teva posted a $5.7 million good-faith deposit and framed the bid as consistent with its Pivot to Growth business-development screen. Higher bids can still emerge at auction. (Link)
  13. Beyond Air, Inc. (Nasdaq: XAIR) has agreed to sell its controlling stake in NeuroNOS Israel Ltd. to Tel Aviv-listed UNIVO Pharmaceutical Industries (TASE: UNVO) for equity, warrants and up to $32.5 million in milestones. Beyond Air is selling 5,000,000 ordinary shares, about 58% of NeuroNOS on a fully diluted basis. Consideration is UNIVO ordinary shares equal to 19.99% of UNIVO’s issued capital, five-year warrants on a further 19.99% of UNIVO awards exercisable at $0.01, plus up to $6.5 million in cash development milestones and up to $26 million in commercial milestones. NeuroNOS is developing blood-brain-barrier-crossing small molecules that regulate nitric oxide, including BA-102 for autism spectrum disorder and Alzheimer’s and BA-101 for glioblastoma, both still preclinical. The sale lets Beyond Air concentrate on its nitric-oxide device franchise. (Link)
  14. Savista, the Alpharetta-based healthcare operations and revenue cycle management company, has acquired ABW Medical, an ambulatory revenue cycle management provider serving federally qualified health centres, medical groups, MSOs and virtual care platforms. Savista is buying its way out of a single-segment concentration. Its existing base is acute: more than 800 clients across 49 states, an Epic-certified training workforce and cancer registry services built over 35 years. ABW Medical adds the non-acute end, including community health centres, FQHCs, rural providers and virtual care, plus preferred RCM partner status inside the athenahealth ecosystem. That diversifies EMR exposure away from Epic dependence and adds safety-net billing around Medicaid wraparound payments. Clients pick up Savista’s global delivery scale and eligibility, coding and A/R tooling. (Link)
  15. Eqwal Group has acquired Atlantic Pro Care, the Portland, Maine prosthetics and orthotics practice, extending the French patient-care network’s East Coast footprint. Eqwal is a global prosthetics and orthotics patient-care group that already owns Steeper in the UK and has been rolling up US clinics including United Prosthetics, American Orthopedics, Optech, South Beach Prosthetics and Prosthetic & Orthotic Group. Atlantic Pro Care, founded in 1993 by J.P. Donovan in Portland, fits custom devices for patients with upper- and lower-limb loss and spinal conditions and handles assessment, fabrication, fitting and rehab. The buyer framed the tuck-in as deepening US patient-care density rather than adding a product brand. No purchase price was published. (Link)
  16. Thurston Group, the Chicago healthcare-focused private equity firm, has made a platform investment in Pixel Health, a Holyoke, Massachusetts provider of IT consulting and managed services to hospitals and large physician groups. Thurston is entering healthcare IT services for the first time through Pixel Health, founded in 2001 and built into a multi-brand group spanning strategy and transformation consulting, managed IT services, and product sales and licensing. Managing partner Dan Davis framed the deal as consistent with the firm’s practice of backing leaders in high-growth healthcare verticals. The sponsor has installed Brad Mondschein, previously the company’s chief operating and legal officer, as chief executive. The investment case is outsourced IT for health systems that cannot staff internally against rising cybersecurity, interoperability and AI-integration complexity. (Link)
  17. BV Investment Partners-backed Imagenet has acquired Analytica Consulting, the California data engineering and artificial intelligence firm, in a transaction that closed on 21 August 2026. Imagenet is moving from transaction-processing BPO toward an end-to-end data and AI solutions position for payers. Analytica Consulting, founded in 2015, brings cloud data warehousing, automated ETL pipelines, enterprise visualisation, data science and governance. The commercial angle is in-situ modernisation: layering pipelines and machine learning models on top of health plans’ existing core systems rather than requiring replacement, and applying prescriptive models to denial trends across digital mailroom, claims adjudication and contact centre lines. The target retains its government, life sciences, manufacturing and education clients. (Link)
  18. Switchboard Health has acquired virtual musculoskeletal provider Livara Health, formerly SpineZone, and closed an oversubscribed equity round of more than $5 million backed by First Trust Capital Partners, Route 66 Ventures, A1 Health Ventures, Allumia Ventures and Martin Ventures. The acquisition converts Switchboard from a referral navigation software layer into a value-based care delivery provider. Livara, founded by orthopaedic spine surgeon Kamshad Raiszadeh, pairs orthopaedic physicians with physical therapists and psychosocial providers, and its outcomes were independently validated by the Validation Institute in 2024 at a 43% reduction in MSK spend, largely through avoided low-value surgery. Switchboard reports routed patient volume up 500% over nine months. This is its second acquisition in under a year after Conduce Health. The raise draws both companies’ existing investors plus new backers. (Link)
  19. WellStack, the Madison, Wisconsin healthcare data platform led by Chief Executive Rich Waller, has acquired DeLorean Artificial Intelligence, the predictive analytics and risk stratification company led by Chief Executive Severence MacLaughlin, to build an end-to-end healthcare decision intelligence platform.WellStack runs an agentic healthcare data platform with a managed data foundation, analytical studio and modular Decision Hubs. DeLorean AI adds continuous evaluation of clinical, claims and operational data to flag emerging risks, predict adverse events and recommend next actions. The combination targets the gap between data aggregation and intervention, moving customers from what happened to what to do about it. Client case studies cite improved patient adherence, reduced avoidable utilisation and revenue optimisation. MacLaughlin framed the merger as necessary for deep integration with health system data lakes and EMRs. (Link)
  20. ALIS, the Chicago-based senior living clinical and operational software platform, has acquired the Ella and elbi technology platforms from TapRoot Interventions & Solutions in its first acquisition. ALIS has grown organically from a clinical EHR into an operating system unifying CRM, clinical, billing, AI and business intelligence; Ella and elbi are its first bought capability. The platforms deliver point-of-care, AI-native guidance to frontline caregivers handling dementia and behavioural episodes, using non-pharmacological, person-centred interventions. The economics sit in two measurable outcomes senior living operators are judged on: fewer high-risk behavioural incidents and reduced psychotropic medication reliance, both increasingly tied to reimbursement and length of stay. The platforms also capture behavioural data for population health reporting. Announced at the buyer’s user conference. (Link)
  21. Globus Medical, Inc. (NYSE: GMED) has acquired Higgs Boson Health, the Durham, North Carolina digital healthcare experience company incubated out of Duke University, to build out its surgical intelligence pillar. What Globus is buying is a team of software developers and AI scientists rather than a revenue base. The acquirer frames the technology as part of a surgical intelligence pillar linking outcomes and analytics in a closed loop across the full episode of care. The stated long-term target is 95% good outcomes at ten years in musculoskeletal surgery, and management is treating patient and provider experience as the missing layer of that ecosystem. The deal follows a second quarter reported on 6 August in which sales grew and non-GAAP EPS guidance was raised. (Link)
  22. Ekoscan Integrity Group, the Eurazeo-backed French non-destructive testing group, has signed a definitive agreement to acquire the US-based NDT Digital business of Carestream Health, Inc., adding the INDUSTREX computed and digital radiography portfolio. Ekoscan is buying Carestream Health’s US NDT Digital unit — computed radiography systems, digital radiography detectors and imaging software under the INDUSTREX brand — plus the commercial, applications and service organisation in Rochester, New York. Radiographic imaging joins the buyer’s existing ultrasound and eddy-current lines, making a multi-method inspection platform for aerospace and defence, oil and gas and power generation. Carestream is narrowing to healthcare imaging. Ekoscan has been an active consolidator, backed by Eurazeo and EDF Pulse Ventures. Closing is expected in the fourth quarter of 2026. (Link)
  23. Golden State Dermatology, the physician-owned platform backed by Sorenson Capital and Yukon Partners, has acquired Summit Dermatology in Colorado Springs, its first move outside California. Golden State Dermatology has been a California story, roughly 45 locations and more than 125 providers built through steady practice tuck-ins with Sorenson Capital and Yukon Partners behind it. Summit Dermatology, led by board-certified dermatologists Kevin Whaley and Jeanne Osborn, is the first out-of-state platform entry and opens the Colorado market. The target offers medical and procedural dermatology including skin cancer screening and Mohs micrographic surgery, and retains its location, phone number and staff. Founder Ed Becker frames the strategy as building the leading comprehensive dermatology network across the Western US. (Link)
  24. Regent Surgical has added Integrated Surgical Center of Arizona, an Avondale multispecialty centre owned by IMS Care, AZ Heart Arrhythmia Associates and Valley GI Consultants, to its ambulatory surgery centre network. Regent Surgical, founded in 2001 and headquartered in Nashville, is a developer and operator of ambulatory surgery centres that has grown from 8 to 32 centres in eight years on site-neutral payment economics. The Arizona addition is a physician-partnership structure rather than an outright buyout: ISCA is owned by IMS Care, the state’s largest independent multispecialty physician group, cardiac electrophysiology group AZ Heart Arrhythmia Associates, and Valley GI Consultants. The strategic value is cardiac migration into outpatient settings across greater Phoenix. Regent also runs a joint venture with Cleveland Clinic. (Link)
  25. Great Point Partners-backed VetnCare has acquired Geary Veterinary Hospital, the Walnut Creek, California practice founded in 1979 and led by Dr. Gillian Hamilton and Dr. Erica Weiss. Great Point Partners, the Greenwich healthcare-only investor, backed VetnCare in 2022; Geary is the seventh acquisition since, and the second in roughly six weeks after Holistic Veterinary Care in Oakland on 14 July. The company has more than doubled in size in three years under that ownership. The model is regional density rather than national scale: VetnCare concentrates in Northern California, and Geary deepens the East Bay position with a practice offering wellness and preventive care, diagnostics and imaging, surgery, dental and senior pet care. (Link)
  26. Gravity 360, Inc., the Covington, Kentucky parent of Gravity Diagnostics, has acquired Med-Lake Laboratory, LLC, a CLIA-certified, CAP-accredited high-complexity clinical laboratory in Milledgeville, Georgia. Gravity 360 is building a regional laboratory platform across the southern United States, and Med-Lake gives it an operating base outside Kentucky for the first time. Founded in 2018, the target serves physician practices, skilled nursing facilities, behavioural health providers, judicial programmes and urgent care clinics across Georgia and Alabama, with a testing portfolio spanning clinical toxicology, blood and clinical chemistry, PCR infectious disease and reference services. Rather than consolidating volume into Kentucky, the buyer is retaining the Georgia laboratory, its team and its courier network as the foundation for further expansion. (Link)
  27. The Landes Group, the Dallas healthcare real estate investment firm, has completed its acquisition of Encore Medical Center in Bryant, Arkansas from Arkansas Heart Hospital and finalised a long-term lease with the University of Arkansas for Medical Sciences, financed with CGA Capital. The Landes Group has closed on a 108,055 square foot, 53-bed hospital and simultaneously locked in its tenant. UAMS gains capacity without deploying capital, paying annual rent reported at roughly $8.16 million with 2.1% escalation and a purchase option in ten years. That structure is the firm’s core strategy: single-tenant, net-leased healthcare assets where ownership is paired with financing that preserves provider capital. Longstanding financing partner CGA Capital supported the transaction, extending a relationship spanning more than $1.2 billion. Arkansas Heart Hospital operates the facility through 30 September, with UAMS assuming control on 1 October. (Link)
  28. Calera Capital-backed Cypress Health Partners has added Boston Sports Medicine’s ten outpatient clinics to the Bay State Physical Therapy network, effective 27 August. Cypress Health Partners, the Calera Capital-backed outpatient physical therapy platform operating across the Northeast, has partnered with Boston Sports Medicine, one of Greater Boston’s most established physical therapy providers. BSM’s ten outpatient clinics join the Bay State Physical Therapy network, expanding access across Massachusetts communities after more than 25 years of referral-base building. The transaction lands as the outpatient PT sector shifts from pure density plays toward a second phase of value creation focused on patient acquisition and reimbursement yield from existing clinical capacity. (Link)

Venture Deals and Other

  1. RA Capital has joined a $120 million Series C for AusperBio Therapeutics that will fund the Phase 3 registrational program for a functional hepatitis B candidate, taking capital raised since 2024 past $340 million.AusperBio, which operates from Hangzhou and California, closed the $120 million Series C on 31 August led by a new strategic investor, with RA Capital Management joining and existing backers HanKang Capital, Sherpa Capital, InnoPinnacle Fund, Qiming Venture Partners, YuanBio Venture Capital and CDH Investments returning. Proceeds fund the Phase 3 registrational program and commercialisation work for lead candidate AHB-137, advance next-generation candidate AHB-171, and support combination-therapy development for chronic hepatitis B. The round is the largest venture check in this week’s book and is a China-plus-US therapeutics financing rather than a services deal. (Link)
  2. The Gates Foundation has committed up to $35 million to ProFound Therapeutics, including $20 million initially, to find placental and serum protein targets for preeclampsia and eclampsia. ProFound Therapeutics uses its ProFoundry platform against the expanded human proteome. The Gates money funds discovery of novel proteins expressed in placenta and serum from women with preeclampsia and eclampsia, new drug targets and biomarkers, and a disease-specific AI tool. The initial $20 million is committed now; the balance is contingent on program progress. This is foundation capital rather than a priced venture round, and it sits beside rather than inside the company’s existing equity syndicate. Announced 27 August. (Link)
  3. TJ Parker, general partner at Matrix, has led a $26 million Series A in Metriport, with participation from ARTIS Ventures and Y Combinator, taking the open-source healthcare data infrastructure company to $28.4 million raised. Matrix led the round through TJ Parker, whose stated rationale is channel evidence: he sees dozens of consumer health companies each year and the strongest ones increasingly build on Metriport. The company was founded in 2022 by former AWS engineer Dima Goncharov and Colin Elsinga. The differentiator investors are underwriting is open-source infrastructure against legacy black-box interoperability tools, accessible via a single API, cloud warehouse connection or native EHR application. Customers include Amazon One Medical, Sollis Health and Color Health. Proceeds fund AI chart summarisation and agentic workflows for care teams. (Link)
  4. Define Ventures has led a $25 million Series B in Arintra, with participation from existing investors Peak XV Partners, Yale New Haven Health Center for Health Care Innovation, Endeavor Health Ventures, Y Combinator, Counterpart Ventures, Ten13 and Spider Capital. Define Ventures led the round, taking Arintra’s total funding to $51 million. The investment case rests on measurable throughput: the platform processes more than $5 billion in annual claim value for health systems representing over $50 billion in combined net patient revenue, and reports a 5.1% increase in compliant revenue capture, 32% cost reduction and 43% fewer coding-related denials. Endeavor Health, an early adopter, backed both the Series A and B. Partner Chirag Shah argued no prior solution had been comprehensive enough to move the bottom line. Proceeds fund enterprise expansion and deeper specialty coverage. (Link)
  5. Wing Venture Capital, Initialized Capital, Sozo Ventures, Hawktail, Lightspeed Venture Partners, Third Kind Venture Capital, Liquid 2 Ventures and SV Angel have backed Outer Bio with roughly $23 million as the Cambridge company exits stealth with its Yuna human-skin platform. What the syndicate is funding is a data asset rather than a clinical one: Yuna keeps full-thickness human skin alive and measurable for four weeks against roughly one week for conventional explants, generating longitudinal multi-omic data that improves the machine learning models over time. The commercial route is consumer skincare first, with partnership revenue already flowing. Founded in 2020 by chief executive Michael Polansky, with Stefani Germanotta on the board. The round size and the syndicate signal investors are underwriting a compounding biological dataset rather than a single product launch. (Link)
  6. Saga Ventures has led $22.5 million in seed and Series A funding for Hike Medical, joined by Indicator Ventures, Fifth Down Capital, RiverPark Ventures, strategic investor Orthofeet, Inc. and angels including Monaco chief executive Sam Blond and Jerod Mayo. Max Altman of Saga Ventures led the financing, and his stated thesis is vertical integration: owning the entire value chain end to end rather than layering software on a broken industry. The market economics justify it, with roughly $100 billion spent annually on orthotics, prosthetics and durable medical equipment and, per the company’s own research, 60 cents of every dollar lost to waste, remakes and fraud. Operating metrics already show remake rates cut from one in 15 to one in 400. Strategic investor and commercial partner Orthofeet participated. Proceeds fund hiring in San Francisco and manufacturing in Peoria, Illinois. (Link)
  7. Costanoa has led a $17 million Series A in Onos Health, joined by Flare Capital Partners and strategic investor CVS Health Ventures, the corporate venture arm of CVS Health Corporation (NYSE: CVS). The strategic money matters commercially: Aetna is already a customer, and the company says it is trusted by three of the six largest US health plans. Costanoa partner Amy Cheetham framed behavioural health as one of the largest and least understood categories in healthcare, with wide cost variation and low correlation to quality. Reported outcomes include a 35% improvement in clinical standard adherence and a 6%-plus cut in behavioural health programme costs within twelve months. Proceeds scale the decision-support tools payers use to manage behavioural benefit design and utilisation. (Link)
  8. Neotribe Ventures, Listen and Village Global have funded a $12 million round for Boston-based Legato, which has emerged from stealth to commercialise AI hearing-assistance glasses. Neotribe founder and managing director Kittu Kolluri framed the investment as a bet against the industry’s design orthodoxy, arguing that decades spent making hearing aids invisible has suppressed adoption and that positioning assistance as a style choice is the route to the market. The defensible asset is intellectual property: four granted patents and more than 20 pending applications. The competitive set is formidable, including EssilorLuxottica’s Nuance Audio and hearing features from Apple and Samsung. Proceeds fund a launch in the coming months and further development. (Link)
  9. August Global Partners has led a $10 million convertible note financing for Shape Memory Medical, joined by fellow new investor Taiwania Capital alongside existing backers HBM Healthcare Investments, Earlybird Venture Capital and WexMed II. The convertible structure defers valuation until clinical readouts land. Partner Davian Sim argued clinicians treating aortic aneurysms and dissections have long relied on repurposed materials, and identified an inflection point as two programmes advance. Proceeds fund follow-up in the AAA-SHAPE pivotal trial, fully enrolled at 180 patients across 48 centres, and the FLAGSHIP feasibility study. Both new investors also support Asia-Pacific expansion. HEAL Venture Lab assisted; the note sits ahead of those readouts rather than pricing the company now. (Link)
  10. Redesign Health has provided $2.25 million in seed funding to OmicsBank, the clinical data infrastructure company founded in 2025 by serial entrepreneurs Sumit Sinha and Vijay Goel.Redesign Health is the sole named backer of this seed round. Head of ventures Neil Patel was explicit about the underwriting order, saying the firm backed the founders first and the market second, citing five companies built between them and the relationship-intensive work of winning hospitals one at a time. The asset being capitalised is a deployed data network: infrastructure inside 90-plus hospitals and laboratories across South Asia, Southeast Asia and the Middle East, covering 12.5 million longitudinal records, 30 million DICOM images, six million pathology slides and 500,000 whole-genome sequences. Proceeds fund US and biopharma expansion. (Link)

CLICK HERE to sign up
for all news and updates

Spenser Lin No Comments

Healthcare News, Deals, and Investments Update July 27th, 2026

LECO_Weekly-Healthcare-News_7-27-2026Download
  1. Longshore Capital Partners entered a strategic growth partnership with revenue cycle management provider Prochant. Chicago-based Longshore Capital Partners, a lower middle-market private equity firm that takes control positions in North American services businesses with $5 million to $15 million of EBITDA, invested in Prochant, a Charlotte, North Carolina technology-enabled RCM provider serving home medical equipment, DME, infusion and specialty pharmacy operators. Terms were undisclosed. Capital will fund technology, analytics, AI and automation investment, service capacity expansion, new revenue cycle product development and talent acquisition, alongside acquisitions in core markets. Longshore is backing an existing management team under CEO Joey Graham, preserving leadership and culture while accelerating investment in a recurring-revenue outsourced services model. (Link)
  2. SkyKnight Capital, L.P. agreed to acquire a controlling position in Apex Infusion from FFL Partners, which retains a minority stake alongside the clinician-led management team. SkyKnight Capital, a San Francisco private equity firm, signed a definitive agreement to partner with Apex Infusion, a Signal Hill, California omnichannel infusion services provider founded in 2006. FFL Partners, which completed its investment in 2024, remains a minority shareholder, and Apex’s clinician-led management retains significant ownership and continues to lead the business. Apex delivers therapy through a home infusion nursing network and roughly 40 ambulatory infusion suites. SkyKnight intends to fund new market entry, health system and payor partnerships, and technology-enabled access initiatives across a site-of-care shift thesis. (Link)
  3. Winterbird Partners made a growth investment in Minneapolis-based Microsoft services partner Emergent Software. Winterbird Partners invested in Emergent Software, a Minneapolis, Minnesota Microsoft services partner specializing in data modernization, AI deployment, cloud transformation, application development and managed services. Deal value was not disclosed. Led by CEO Jamie Anderson, Emergent manages solutions across the Microsoft ecosystem including Fabric, Azure, Copilot, Foundry and modern data platforms. Proceeds will fund headcount expansion, additional service capabilities and entry into new geographies. For Winterbird, the transaction is a bet on the durability of enterprise AI and data-platform implementation, backing a founder-led services firm against a single hyperscaler ecosystem rather than horizontal consultancy model. (Link)
  4. Healthcare technology platform Focus entered a definitive agreement to acquire Plano, Texas-based managed technology services company GuideIT. Focus, a Chicago-headquartered healthcare technology services company, agreed to acquire GuideIT, a nationally recognized managed technology services provider offering managed IT, cybersecurity, cloud integration, IT and clinical service desk, and medical data services. Terms were undisclosed; GuideIT will operate as GuideIT, A Focus Company. Focus supports more than 100 electronic health record and practice management systems and is consolidating fragmented healthcare vendor relationships into a single accountable partner. GuideIT CEO and board member Russell Freeman described a deliberate partner selection process. The acquisition scales Focus’s Unified Healthcare Platform thesis through capability breadth rather than geographic density. (Link)
  5. Knox Lane completed its $437 million take-private acquisition of Cross Country Healthcare, Inc. (formerly NASD: CCRN), concurrently selling the locums division to portfolio company All Star Healthcare Solutions. Growth-oriented investment firm Knox Lane closed its all-cash acquisition of Cross Country Healthcare at $13.25 per share, valuing the technology-enabled workforce solutions company at roughly $437 million and ending its NASD listing. The deal follows a terminated agreement with Aya Healthcare. Knox Lane simultaneously moved Cross Country’s locum tenens division into All Star Healthcare Solutions, an existing portfolio company, creating immediate platform consolidation. Managing Partner John Bailey and Partner Shamik Patel cited the company’s position at the intersection of workforce services and technology. Joel Tremblay, formerly of Medical Solutions, was installed as CEO, succeeding co-founder Kevin Clark. (Link)
  6. Care Career acquired MAS Medical Staffing, completing its first acquisition phase and lifting consolidated annual revenue beyond $150 million. Woodbridge, New Jersey-based Care Career, a healthcare workforce technology organization led by CEO Siva Konatham, acquired Manchester, New Hampshire-based MAS Medical Staffing, including its travel, allied and per diem operations and technology assets. Financial terms were undisclosed. This is Care Career’s seventh acquisition in 24 months, following IDR Healthcare in February 2026, Source Medical Staffing in October 2025, and four firms in May 2025. The completed first round now exceeds $150 million of annual revenue, with signed LOIs expected to close in Q3 2026 pushing consolidated revenue past a quarter billion by year-end, aided by MAS’s Maestra workforce platform. (Link)
  7. Equality Asset Management-backed Mindoula acquired Valera Health and Janus Healthcare Partners in a double transaction expanding its whole-person care enablement platform. Mindoula, the Silver Spring, Maryland behavioral health company backed by Equality Asset Management, simultaneously acquired New York-based virtual mental health provider Valera Health and Duxbury, Massachusetts psychiatric collaborative care provider Janus Healthcare Partners. Terms were undisclosed. These are Mindoula’s third and fourth acquisitions since its 2013 founding, following Care at Hand and 180 Health Partners. Valera contributes more than 300 multi-state behavioral providers and specialization in suicide risk reduction, DBT and serious mental illness; Valera had itself raised $74.3 million and acquired Vita Health in 2025. Janus adds psychiatry CoCM capability, positioning Mindoula for value-based contracts with payers and health systems. (Link)
  8. Beacon Behavioral Partners entered Ohio and Michigan through a partnership with Ohio- and Michigan-based Pure Psychiatry, adding a 17-location outpatient platform. Plano, Texas-based Beacon Behavioral Partners, a growing network of independent psychiatric practices, acquired Pure Psychiatry, establishing its first presence in Ohio and Michigan and marking one of its largest expansions to date. Financial terms were undisclosed. Pure Psychiatry, led by founders Taylor Hennrick, PA-C, Sarang Patel, PA-C and Dr. Rakesh Amin, provides psychiatric care across all age groups including medication management for anxiety, depression, ADHD and bipolar disorder. Beacon will supply operational, administrative and strategic support to fund de novo clinic openings and provider recruitment. The deal follows Beacon’s appointment of Rob Jardeleza as CEO roughly a week earlier. (Link)
  9. Truehelm-backed Wildflower Health acquired digital pelvic floor platform Every Mother, marking its entry into direct-to-consumer women’s health. Wildflower Health, the San Francisco tech-enabled women’s health company backed by Truehelm, acquired Every Mother, a clinically validated core and pelvic floor therapy platform founded by Allison Rapaport. Terms were undisclosed. Wildflower operates enterprise infrastructure connecting commercial health plans, risk-bearing provider groups and patients across all 50 states, supporting thousands of women’s health providers. Every Mother contributes HSA/FSA-eligible on-demand exercise programs addressing diastasis recti, urinary incontinence, pelvic organ prolapse and pelvic pain. Strategically, the acquisition adds a consumer subscription revenue channel to an enterprise contracting model and extends patient relationships beyond the traditional six-to-twelve-week postpartum drop-off. (Link)
  10. DuneGlass Capital-backed Aviva Aesthetics expanded into Ohio through a partnership with Avon, Ohio-based Vitality Health. Aviva Aesthetics, the Chicago-based entrepreneur-owned medical aesthetics platform launched in 2024 with healthcare services independent sponsor DuneGlass Capital, partnered with Vitality Health, a medical aesthetics and wellness practice in Avon, Ohio founded in 2014 by Alana Mercer, PA-C. Terms were undisclosed. This is Aviva’s eighth partnership of 2026 and its first Ohio location, deepening Midwest presence. Vitality Health provides injectables, laser treatments, skin rejuvenation, weight management and hormone optimization. Aviva’s Entrepreneur Equity structure explicitly positions against traditional private equity roll-ups, allowing founders to retain full equity and control while accessing scale economics and back-office support. (Link)
  11. PE-backed Premier Care Dental Management acquired cosmetic dentistry practice Brookline Smile Artists in Massachusetts. Premier Care Dental Management, the New Hyde Park, New York dental clinical organization operating under the Dental365 brand and backed by The Jordan Company, added Brookline, Massachusetts-based Brookline Smile Artists to its network. Terms were undisclosed. PCDM supports practices across New York, Connecticut, New Jersey, Pennsylvania, Ohio, New Hampshire, Massachusetts and Rhode Island, and has pursued an acquisition-led growth cadence including multiple Ohio additions earlier in 2026. The tuck-in extends the sponsor-backed platform further into higher-margin cosmetic dentistry, a service line with meaningful cash-pay mix, while continuing the roll-up strategy aimed at retiring and scaling-back owner-dentists across the Northeast. (Link)
  12. Shore Capital Partners-backed Innovate 32 partnered with Houston-based Post Oak Dental, expanding its Texas dental support organization footprint. Innovate 32, the Nashville-based dental services organization formed by Chicago lower middle-market private equity firm Shore Capital Partners, closed a partnership with Post Oak Dental, an established Houston, Texas practice. Terms were undisclosed. Under CEO Josh Johnson and a board combining dentists, multi-site healthcare operators and private equity executives, Innovate 32 has assembled a network across Texas, Tennessee, Florida and the Mid-Atlantic since its 2024 founding. Post Oak Dental retains its clinical focus while gaining management infrastructure. For Shore, the affiliation continues a disciplined buy-and-build in general dentistry, prioritizing clinician alignment and local leadership over transactional roll-up. (Link)
  13. Dentalcorp entered the U.S. market with the acquisition of Florida-based Northstar Dental Partners. Toronto-based Dentalcorp, one of the largest dental support organizations in North America, acquired Northstar Dental Partners, a Boca Raton-headquartered group supporting 21 dental practices across South Florida, the Treasure Coast, Southwest Florida and Central Florida. Founder and CEO Dr. Jordan Tomalty retains an ownership stake and will remain instrumental to continued growth. Combined with Dentalcorp’s Canadian network, the partnership brings the total to over 650 supported practices. (Link)
  14. vybe urgent care acquired Liberty Urgent Care’s Horsham and Hatfield centers, supported by growth-oriented debt financing from Live Oak Bank. vybe urgent care, the leading independent urgent care operator in greater Philadelphia, acquired Liberty Urgent Care’s two Montgomery County, Pennsylvania centers, expanding its network from 16 to 18 sites. Terms were undisclosed. The transaction was funded through a recent growth-oriented refinancing completed with Live Oak Bank, which vybe intends to draw on for further acquisitions and de novo development. Liberty founder Erik Soiferman, D.O. joins as Vice President of Occupational Medicine Services, strengthening vybe’s occupational health and workers’ compensation capabilities. The debt-funded structure allows the independent operator to consolidate a fragmented regional market without an equity sponsor. (Link)
  15. Ares Management Corporation (NYSE: ARES) and Rubicon Founders-backed US Heart & Vascular acquired Tennessee physician-owned practice Apex Vascular and its outpatient center. US Heart & Vascular, the Nashville-area cardiovascular support services platform backed by funds managed by the Private Equity Group of Ares Management (NYSE: ARES) alongside Rubicon Founders, acquired Apex Vascular and Apex Vascular Outpatient Center. Terms were undisclosed. Headquartered in Lenoir City, Tennessee, Apex has served East Tennessee for nearly two decades across Knoxville, Crossville, Harrogate, Decatur, Sevierville and Oak Ridge, treating peripheral artery disease, varicose veins, carotid artery disease and dialysis access. Founder Christopher Pollock, MD cited access to resources for regional expansion. The tuck-in deepens USHV’s density in a specialty prized for recurring outpatient procedure volume. (Link)
  16. Paradigm Oral Health bought back BlackRock, Inc.’s (NYSE: BLK) Long Term Private Capital stake in a surgeon-led transaction backed by a Warburg Pincus-led group including Goldman Sachs (NYSE: GS) Alternatives and Sixth Street. Lincoln, Nebraska-based Paradigm Oral Health repurchased BlackRock Long Term Private Capital’s ownership stake, returning majority control to its surgeons and management. The buyback is funded by a significant investment led by Warburg Pincus, a private partnership since 1966, in partnership with Goldman Sachs (NYSE: GS) Alternatives and Sixth Street. Terms were undisclosed. Founded in 2018 by David Rallis, DDS, MD, Paradigm operates an oral surgery and digital dentistry platform built to attract and retain surgeons. The structure is notable for reversing conventional sponsor control: incoming capital supports clinician majority ownership, technology investment, advanced training and de novo clinic expansion. (Link)
  17. Groups Recover Together acquired Better Life Partners in its first-ever acquisition, doubling its New England patient volume.Burlington, Massachusetts-based Groups Recover Together, the value-based opioid use disorder treatment provider backed by Oak HC/FT, Bessemer Venture Partners, Transformation Capital, RRE Ventures, Optum Ventures and Kaiser Permanente Ventures, acquired Better Life Partners in a transaction that closed March 31. Financial terms were undisclosed. Better Life Partners, founded in Vermont in 2018 and backed by aMoon, Alumni Ventures, F-Prime Capital, Maverick Ventures and .406 Ventures, had raised $26.5 million in a 2023 Series B but experienced financial distress. CEO Cooper Zelnick highlighted mental health and virtual primary care capabilities the company intends to scale nationally beyond New England. (Link)
  18. Ohio-based Cardinal Health (NYSE: CAH) agreed to acquire the Diabetes Health business of AdaptHealth Corp. (NASD: AHCO) and, in its entirety, NMS Capital-backed Strive Medical for approximately $360 million in cash. Cardinal Health (NYSE: CAH), headquartered in Dublin, Ohio, deployed roughly $360 million of cash across two definitive agreements to scale its at-Home Solutions platform, subject to working capital adjustments. The AdaptHealth (NASD: AHCO) unit serves over 225,000 patients annually through a centralized mail-order CGM model, while NMS Capital portfolio company Strive Medical adds urology, wound care, ostomy and incontinence supply distribution to 20,000-plus patients. Both transactions build on Cardinal’s Advanced lDiabetes Supply acquisition and are expected to be accretive to non-GAAP EPS within twelve months of close, extending the Ohio distributor’s consolidation of fragmented direct-to-patient supply channels. (Link)
  19. Surgery Partners, Inc. (NASD: SGRY) agreed to sell its ownership interests in Mountain View Hospital and Idaho Falls Community Hospital to Intermountain Health for approximately $795 million. Surgery Partners (NASD: SGRY), the Brentwood, Tennessee short-stay surgical facility operator, placed into escrow signature pages to sell its Idaho Falls hospital interests to existing partner Intermountain Health, a Utah-based nonprofit system of 34 hospitals and roughly 400 clinics. The transaction values the combined facilities at approximately $1.15 billion, with total consideration to Surgery Partners of about $795 million before purchase price adjustments. Physician ownership of Mountain View Hospital is unchanged. CEO Eric Evans framed the divestiture as portfolio optimization, refocusing capital toward ambulatory surgery centers. The company reaffirmed 2026 revenue guidance of $3.35–$3.45 billion excluding transaction impact. (Link)
  20. Gentherm Incorporated (NASD: THRM) acquired Ohio-based Innovative Medical Equipment, LLC, maker of the ThermaZone thermal therapy device. Gentherm (NASD: THRM), the Novi, Michigan thermal management and pneumatic comfort technology leader, acquired Innovative Medical Equipment, a Cleveland-area, Ohio provider of the ThermaZone non-opioid hot-and-cold thermal therapy system. Terms were undisclosed. Founder and President Brad Pulver framed Gentherm’s scale and global operating footprint as the growth enabler for the Ohio business. Management expects revenue synergies from cross-selling ThermaZone through Gentherm’s expanded healthcare customer channels. Announced alongside record Q2 2026 revenue of $416 million, raised full-year guidance and a new $400 million repurchase authorization, the deal advances Gentherm’s strategic pivot toward higher-margin medical adjacencies. (Link)
  21. RS2 Healthcare Partners, the Boston-based private equity firm formerly known as Riverside Partners, completed an investment in KMM Group, a Hatboro, Pennsylvania-based vertically integrated precision contract manufacturer serving the medical device industry. RS2 Healthcare Partners, founded in 1989 and rebranded from Riverside Partners in May 2026 to formalize an exclusive lower-middle-market healthcare strategy, closed an investment in KMM Group. Terms and stake size were undisclosed. The firm has raised $1.6 billion in total capital commitments since inception and concentrates on pharma services, medical device contract manufacturing and technology-enabled healthcare, supported by healthcare, clinical and AI advisory boards. KMM produces complex, tight-tolerance components for failure-intolerant end markets. J. Mark King joins as President and CEO, while co-founders John Shegda and Eric Wilhelm move to Chief Technology Officer and Executive Vice President, Business Transformation, preserving customer and employee continuity under sponsor ownership. (Link)
  22. Eurofins Scientific (EUFI.PA) agreed to acquire Element Materials Technology’s Life Sciences Testing Services business in North America for an enterprise value of $400 million. Eurofins Scientific, a global leader in bioanalytical testing, reached agreement with Element Materials Technology to acquire its North America Life Sciences Testing Services business, encompassing biopharma product testing, environmental testing and food testing across a network of 27 laboratories and facilities employing approximately 750 FTEs. The business is expected to generate over $150 million in 2026 revenues with profitability in line with the Eurofins Group average. The transaction expands Eurofins’ geographic footprint in key U.S. and Canadian regions where it has been underrepresented and is expected to close in Q4 2026 subject to customary regulatory approvals. (Link)
  23. Repligen Corporation (NASD: RGEN) agreed to acquire BioLife Solutions, Inc. (NASD: BLFS) for a total enterprise value of approximately $1.5 billion. Repligen will acquire BioLife in a cash-and-stock transaction valued at $31.00 per BioLife share ($11.25 cash plus 0.1442 shares of Repligen common stock), representing a 24% premium to the 90-day VWAP. The deal adds BioLife’s market-leading biopreservation media platform (including CryoStor) and cell-processing tools that support 18 commercially approved therapies and the majority of U.S. commercially sponsored cell-based trials. The transaction is expected to be accretive to growth, margins and adjusted EPS (at least 5 cents in year one and 25 cents in year two) with $20–30 million of synergies; closing is targeted for Q4 2026. (Link)
  24. Nordic Capital agreed to sell life sciences software platform ArisGlobal to Dassault Systèmes (Euronext Paris: DSY) for up to $2 billion, marking a full exit for the Swedish sponsor. Nordic Capital, which manages approximately €39 billion, is exiting ArisGlobal entirely in a sale to Dassault Systèmes (Euronext Paris: DSY) reported at $1.8 billion cash plus a $200 million earnout. Nordic first invested in 2019 via its ninth fund at a reported $700 million enterprise value and added to its stake in 2021. Under Nordic’s ownership the Waltham, Massachusetts company converted to SaaS, completed two bolt-ons and is expected to generate roughly $175 million of 2026 revenue, processing 12 million safety cases annually for 200-plus customers. Closing is expected in the second half of 2026. (Link)
  25. Vireo Growth Inc. (CSE: VREO; OTCQX: VREOF) entered a definitive agreement to acquire certain cannabis cultivation, manufacturing and retail assets of The Cannabist Company Holdings Inc. across five markets for up to $35 million. Vireo Growth, through subsidiary Vireo Health of Arcadia, agreed to acquire selected operations from Cannabist subsidiaries in Colorado, Illinois, Massachusetts, New Jersey and West Virginia for total consideration of up to US$35 million (up to US$18.75 million cash at closing plus up to US$16.25 million in seller notes), subject to adjustments and regulatory approvals. The staged transaction is expected to add up to 25 dispensaries plus cultivation and production assets, deepening Vireo’s Colorado presence and adding four new states. Closing is targeted through 2026 into 2027 amid Cannabist’s CCAA and Chapter 15 proceedings. (Link)
  26. Vireo Growth Inc. (CSE: VREO; OTCQX: VREOF) agreed to acquire Planet 13 Holdings Inc. (CSE: PLTH; OTCQX: PLNH) in an all-share merger. Vireo Growth entered a definitive merger agreement to acquire all outstanding equity of Planet 13, with each Planet 13 share converting into 0.015383618 of a Vireo subordinate voting share (16.6% premium to the 20-day VWAP and 24% premium to the closing price as of July 24, 2026). The transaction deepens Vireo’s Nevada and Florida footprints (adding the flagship Las Vegas superstore, additional dispensaries, cultivation/production capacity and licenses) and adds a Waukegan, Illinois dispensary. On a pro forma basis with prior announced deals, Vireo expects to operate approximately 265 dispensaries across 15 states. Closing is subject to stockholder, regulatory and listing approvals. (Link)
  27. First Choice Healthcare Solutions, Inc. (OTCQB: FCHS) and Westin Acquisition Corp. (NASD: WSTN) announced a definitive business combination agreement to create a publicly traded healthcare and wellness company. The transaction values First Choice at a pro forma enterprise value of approximately $650 million and is expected to accelerate its strategic rebrand to Wellgevity 360, a platform focused on longevity, preventative care and personalized biology-driven solutions. Westin will domesticate and the combined company is expected to trade on NASD. Closing is targeted for Q4 2026 subject to customary approvals and conditions. (Link)
  28. Avanos Medical, Inc. (NYSE: AVNS) stockholders approved the company’s $25.00-per-share take-private by American Industrial Partners, valuing the medtech at roughly $1.272 billion. Avanos Medical (NYSE: AVNS) shareholders voted overwhelmingly in favor of the acquisition by affiliates of funds advised by American Industrial Partners, with approximately 99.75% of shares voted supporting the merger, representing about 74.96% of shares outstanding as of the June 18 record date. Holders receive $25.00 per share in cash, an enterprise value near $1.272 billion and a 72.1% premium to the pre-announcement close, plus an 82.8% premium to the 30-day VWAP. All regulatory approvals had been obtained, with closing expected no later than July 27, 2026. The operationally focused industrials investor takes Avanos private, delisting from the NYSE. (Link)
  29. Royalty Pharma plc (NASD: RPRX) acquired a portion of Neurimmune’s royalty interest in cliramitug for up to $425 million. Royalty Pharma (NASD: RPRX) committed up to $425 million to Zurich-based Neurimmune in exchange for a 3% to 4% royalty on worldwide net sales of cliramitug, an investigational anti-amyloid antibody for ATTR cardiomyopathy. The structure front-loads $125 million upfront, with a further $125 million payable in Q1 2027 and $175 million tied to clinical and regulatory milestones. Cliramitug is licensed globally to Alexion, AstraZeneca Rare Disease, which is running the Phase 3 DepleTTR-CM trial. For Royalty Pharma, the transaction buys exposure to the rapidly growing ATTR-CM market; for Neurimmune, it is non-dilutive capital funding its internal pipeline. (Link)
  30. Aurobindo Pharma Limited (NSE: AUROPHARMA; BSE: 524804), through wholly owned subsidiary Apitoria Pharma Private Limited, agreed to acquire 80% ownership control of A1 Biochem Labs (India) Private Limited and A1 Biochem Labs LLC, USA at a $17 million enterprise value. Aurobindo Pharma (NSE: AUROPHARMA; BSE: 524804) is deploying $13.6 million in cash through Apitoria Pharma for an 80% interest in A1 Biochem Group’s contract research business, struck at a $17 million enterprise value on a debt-free, cash-free basis, subject to closing adjustments. The existing promoter retains 20%, and A1 Biochem Labs (India) will absorb A1 Biochem Labs LLC and the CRO business of A1 Biochem Research (India). The target posted FY26 turnover of ₹1,024.42 million and EBITDA of ₹465.46 million — a 45% margin — across Wilmington and Hyderabad labs with 90-plus scientists. Aurobindo is building an integrated CRDMO platform across the API value chain; closing is expected in 90 to 120 days. (Link)
  31. Scancell Holdings plc (AIM: SCLP) and Neuphoria Therapeutics Inc. (NASD: NEUP) announced an all-share merger agreement and associated financing. Scancell will acquire Neuphoria in an all-share transaction; the combined company will operate as Scancell, list on NASD (in addition to AIM) and advance a pipeline of targeted, off-the-shelf active immunotherapies, led by iSCIB1+ in advanced melanoma. Existing Scancell shareholders are expected to own approximately 85.5% and Neuphoria shareholders 14.5% on a pro forma basis (before financing). Concurrent financing of up to $89 million (equity and debt) is intended to fund the global registrational Phase 3 trial. Closing is targeted for late Q4 2026 subject to shareholder and regulatory approvals. (Link)
  32. Footbridge Partners and ALZA Capital Partners sold Ohio-, Pennsylvania- and Michigan-based medical spa platform The Skin Center to an undisclosed middle-market healthcare private equity fund. Footbridge Partners and ALZA Capital Partners exited The Skin Center, a medical spa and cosmetic surgery platform operating 14 locations across Pennsylvania, Ohio and Michigan, selling to an unnamed middle-market healthcare private equity fund in a recapitalization. Terms were undisclosed. Founded in 1981 by Jerry and Dominic Brandy, the company delivers neurotoxins, dermal fillers, laser skin resurfacing, laser hair removal and cosmetic surgery under CEO Eric Warden. Footbridge co-founder and Managing Partner David Rosner credited management and providers for the outcome. The incoming sponsor inherits a platform positioned for de novo openings and further M&A across the consolidating medical aesthetics market. (Link)

Venture Deals and Other

  1. MannKind Corporation (NASD: MNKD) raised approximately $50 million in a private placement led by Frazier Life Sciences. MannKind (NASD: MNKD) closed a roughly $50 million private placement with institutional investors, led by longstanding biotech investor Frazier Life Sciences. The company sold 10,440,838 common shares at $3.89 and pre-funded warrants for 2,412,632 shares at $3.88, with a $0.01 exercise price and no expiry. Proceeds fund general corporate purposes including a $45 million contingent value rights payment triggered by the FDA’s July 23, 2026 approval of Furoscix ReadyFlow for edema in heart failure and chronic kidney disease patients. (Link)
  2. Insight Partners led a $19 million Series A in AI-native provider credentialing platform Assured, with participation from First Round Capital and Kindred Ventures. Insight Partners led Assured’s $19 million Series A, joined by existing backers First Round Capital and Kindred Ventures, bringing total capital raised to $25 million following a $6 million seed in September 2025. Insight Managing Director Teddie Wardi articulated the thesis directly: incumbent credentialing tools function as systems of record while Assured’s agents perform the work itself, verifying data against more than 2,000 primary sources and cutting credentialing time by 30%. Launched in 2024, the NCQA-certified CVO serves over 100 organizations including Houston Methodist. Proceeds expand R&D and go-to-market teams ahead of a privileging product in early 2027. (Link)
  3. Brevy Care raised $4.77 million with participation from GreyMatter Capital to expand Medicaid reimbursement software for family caregivers. Brevy Care, a developer of software helping family caregivers access Medicaid reimbursements, raised $4.77 million in a round including San Francisco-based GreyMatter Capital, a mental and behavioral health-focused venture firm founded in 2021 that typically writes first checks of $250,000 to $1.2 million. The financing brings Brevy’s total capital raised to $4.92 million. GreyMatter’s thesis centers on early-stage innovation in behavioral healthcare delivery and adjacent care-navigation infrastructure. For investors, Brevy addresses a reimbursement-access gap in self-directed Medicaid programs, a payer-funded and demographically supported category as aging populations shift care burden toward unpaid family members. (Link)
  4. Sixth Street Growth led a $120 million Series D in autonomous revenue cycle management platform Candid Health, with participation from Oak HC/FT, 8VC and Y Combinator. Candid Health raised $120 million led by Sixth Street Growth, the dedicated growth platform of Sixth Street, which manages over $135 billion and has invested more than $13 billion across 90-plus companies. Oak HC/FT, 8VC and Y Combinator participated. The round marks a 3x valuation increase over the February 2025 Series C led by Oak HC/FT. Managing Director Alex Katz cited diligence calls with nearly 40 customers and proof points applying agentic AI at scale. Candid reported 190% year-over-year annual contracted run-rate growth and 180% net dollar retention in 2025, targeting the $280 billion US RCM spend. (Link)
  5. Innovation Endeavors and Xora co-led a $21 million Series A in sensor developer Elio, with participation from Kevin Weil, Scribble VC, UpWest and Resolute Ventures. Elio, a Silicon Valley and Israel-based company building sensors designed for artificial intelligence rather than human vision, raised $21 million co-led by Innovation Endeavors and Xora. Kevin Weil and Scribble VC participated, alongside existing investors UpWest and Resolute Ventures, who led the prior round. Total funding reaches $29 million. Founded by former Meta AR/VR executives, Elio embeds computation directly into optics using dynamic micromirror layers that behave like a neural network, letting AI decide what to capture in real time. Investors are backing applications spanning microscopy, semiconductor inspection, robotics and defense drone detection. (Link)
  6. 7wire Ventures and Allumia Ventures co-led an oversubscribed $16.2 million Series A in Karoo Health, joined by First Trust Capital Partners, SpringRock Ventures and Hyde Park Angels. Karoo Health, an Albuquerque, New Mexico cardiovascular technology company led by CEO Ian Koons, closed a $16.2 million oversubscribed Series A co-led by 7wire Ventures and Allumia Ventures, with First Trust Capital Partners, SpringRock Ventures and Hyde Park Angels participating. Managing Partners Lee Shapiro of 7wire and Jeff Stolte of Allumia join the board. Deployed programs have produced independently analyzed reductions exceeding 40% in emergency department visits and inpatient admissions, plus a greater than 10% total cost of care reduction. Karoo supports 600-plus cardiology providers across 11 states; proceeds fund predictive models and health plan expansion. (Link)
  7. FUSE led a $16 million financing in AI-powered concierge primary care platform Prosper Medical, with participation from Aurum Partners, Better.vc, Cal Innovation Fund, Fluent, Latitude Capital, Knoll Ventures and WTI. Prosper Medical, a San Francisco company founded in 2026 by CEO Ryan McQuaid and CMO James Wantuck, MD, raised $16 million led by FUSE alongside Aurum Partners, Better.vc, Cal Innovation Fund, Fluent, Latitude Capital, Knoll Ventures and Western Technology Investment. Investors are backing repeat founders who previously built PlushCare and sold it to Accolade for $450 million. Unlike cash-pay concierge peers, Prosper is in-network with major insurance plans across all 50 states at a $69 monthly membership, using an AI care layer for longitudinal data aggregation and referral coordination. Proceeds expand the physician network and enter new markets. (Link)
  8. Decathlon Capital Partners provided a non-dilutive growth-debt investment to value-based care technology company Health Endeavors. Decathlon Capital Partners, a growth-debt provider with offices in Palo Alto and Park City, made a strategic investment in Health Endeavors, a Farmington, Utah technology partner to Accountable Care Organizations. Deal size was undisclosed, but the structure requires no dilution of existing shareholders. Managing Director Matt Hoffman framed the investment as conviction in value-based care economics. Health Endeavors serves over 2 million patients with 16-plus years of ACO experience and partnerships with Novant Health and Providence. Decathlon targets companies with $4 million to $100 million revenue, 10%-plus growth and near-term visibility to cash-flow-positive status, avoiding equity dilution and loss of control. (Link)
  9. Vensana Capital and Ohio-based Mutual Capital Partners co-led a $30 million Series A in TYBR Health, with participation from Neovate Capital Partners and existing investors. TYBR Health, a Houston, Texas orthopedic biologics company co-founded and led by CEO Tim Keane, PhD, raised $30 million in Series A financing co-led by Vensana Capital and Mutual Capital Partners, the Cleveland, Ohio venture firm managed by Bill Trainor and Wayne Wallace that invests exclusively in Midwest healthcare IT and medical device companies. Proceeds expand commercial access to the FDA-cleared B3 GEL System, a flowable extracellular matrix hydrogel, broaden indications and fund clinical studies on tissue protection during orthopedic surgery. (Link)

CLICK HERE to sign up
for all news and updates